Mereo BioPharma Group plc announced the appointments of two new members to the Company's Board of Directors. Dr. Brian Schwartz, former Chief Medical Officer of Arqule Inc. and Dr. Jeremy Bender, former Vice President of Corporate Development at Gilead Sciences Inc. and recently appointed Chief Executive Officer of Day One Biopharmaceuticals Inc., will join Mereo's Board of Directors. Drs. Schwartz and Bender bring significant oncology drug development and corporate development experience to Mereo. In addition, in order to maintain the maximum number of board members at nine, Paul Blackburn will be leaving Mereo's Board of Directors after a five-year tenure as a Non-Executive Director. The changes to the Mereo Board will be made with effect from October 1, 2020. Dr. Schwartz brings significant experience in oncology drug development in both the biotechnology and pharmaceutical industries. Dr. Schwartz most recently served as Chief Medical Officer of Arqule Inc. where he served as a key member of the management team and managed diverse interdisciplinary teams to advance preclinical and clinical drug development programs in oncology and rare diseases. Dr. Bender is a senior biopharma leader with broad experience driving strategic decisions and transactions. Dr. Bender was recently appointed Chief Executive Officer of DayOne Biopharmaceuticals Inc. He previously served as Vice President of Corporate Development at Gilead Sciences Inc.